BioCentury | Apr 29, 2020
Product Development

April 28 Quick Takes: Syndax gains on leukemia data; plus Supernus, Neurocrine, Avadel, Insilico-Astellas, Innovent-Lilly, Chimerix

...as an add-on treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes. Avadel’s FT218...
...NASDAQ:AVDL) reported top-line results from the Phase III REST-ON trial showing all three doses of FT218...
BioCentury | Dec 4, 2019
Clinical News

Axsome plans Phase III trial for narcolepsy therapy following positive Phase II data

...approved to date that is not a scheduled controlled substance. Avadel Pharmaceuticals plc (NASDAQ:AVDL) has FT218...
BioCentury | Apr 28, 2017
Company News

Avadel restructuring news

...will not affect the allocation of resources to the ongoing Phase III REST-ON trial evaluating FT218...
...sleepiness and cataplexy in patients with narcolepsy. Avadel expects to complete enrollment by year end. FT218...
...operating loss of $5 million. Avadel Pharmaceuticals plc (NASDAQ:AVDL), Dublin, Ireland Business: Neurology, Drug delivery Meghan Sullivan FT218 Avadel...
BioCentury | Dec 20, 2016
Clinical News

FT218: Ph III REST-ON started

...4.5-9 mg oral FT218 in 264 patients. Flamel Technologies S.A. (NASDAQ:FLML), Lyon, France Product: Sodium oxybate delivered via Micropump technology (FT218...
...from N2, N3 and REM sleep stages to N1 Status: Phase III started Milestone: NA Julian Zhu FT218 Sodium oxybate delivered via Micropump technology Flamel...
BioCentury | May 12, 2014
Clinical News

Sodium oxybate delivered via Micropump technology: Clinical trial data

...daytime sleepiness and cataplexy in patients with narcolepsy. Flamel Technologies S.A. (NASDAQ:FLML), Lyon, France Product: Sodium oxybate delivered via Micropump technology...
Items per page:
1 - 5 of 5